After meeting with CRVO’s management and analyzing its recent drug trial results, Boral believes that the company can improve ...

Why Boral Upgraded CRVO After meeting with CRVO's management and analyzing its recent drug trial results, Boral believes that the company can improve the performance of its neflamapimod drug by ...

Roth/MKM initiated a Buy rating on Entrada, with a price target of $29.00, based on positive results from the Phase 2a study of its drug neflamapimod. Additionally, Oppenheimer maintained an ...

Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia ...

Roth/MKM initiated a Buy rating on Entrada, with a price target of $29.00, based on positive results from the Phase 2a study of its drug neflamapimod. Additionally, Oppenheimer maintained an ...